Antiphospholipid antibodies in critically ill COVID-19 patients with thromboembolism: cause of disease or epiphenomenon?

被引：13

作者：

Pavoni, Vittorio ^{[1
,2
]}

Gianesello, Lara ^{[3
]}

Horton, Andrew ^{[4
]}

机构：

[1] Santa Maria Annunziata Hosp, Emergency Dept, Florence, Italy

[2] Santa Maria Annunziata Hosp, Anesthesia & Intens Care Unit, Crit Care Area, Florence, Italy

[3] Univ Hosp Careggi, Dept Anesthesia & Intens Care, Orthoped Anesthesia, Largo Palagi 1, I-50139 Florence, Italy

[4] Univ Utah Hlth, Sch Dent, Salt Lake City, UT USA

来源：

JOURNAL OF THROMBOSIS AND THROMBOLYSIS | 2021年 / 52卷 / 02期

关键词：

COVID-19; Critically ill patients; Venous thromboembolism; Arterial thromboembolism; Antiphospholipid antibodies; Antiphospholipid antibodies syndrome;

D O I：

10.1007/s11239-021-02470-y

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Coronavirus 2019 disease (COVID-19) is associated with coagulation dysfunction that predisposes patients to an increased risk for both arterial (ATE) and venous thromboembolism (VTE) and consequent poor prognosis; in particular, the incidence of ATE and VTE in critically ill COVID-19 patients can reach 5% and 31%, respectively. The mechanism of thrombosis in COVID-19 patients is complex and still not completely clear. Recent literature suggests a link between the presence of antiphospholipid antibodies (aPLs) and thromboembolism in COVID-19 patients. However, it remains uncertain whether aPLs are an epiphenomenon or are involved in the pathogenesis of the disease.

引用

页码：542 / 552

页数：11

共 92 条

[31]

Ambrosino P., Lupoli R., Tarantino P., Di Minno A., Tarantino L., Di Minno M.N.D., Viral hepatitis and antiphospholipid antibodies positivity: a systematic review and meta-analysis, Dig Liver Dis, 47, pp. 478-487, (2015)

[32]

Avein T., Toplak N., Antiphospholipid antibodies in response to infection, Curr Rheumatol Rep, 9, pp. 212-218, (2007)

[33]

Levine J.S., Branch D.W., Rauch J., The antiphospholipid syndrome, N Engl J Med, 346, pp. 752-763, (2002)

[34]

Hughes G.R., Systemic lupus erythematous, Postgrad Med J, 64, 753, pp. 517-521, (1998)

[35]

Cervera R., Espinosa G., Update on the catastrophic antiphospholipid syndrome and the “CAPS Registry, Semin Thromb Hemost, 38, pp. 333-338, (2021)

[36]

Cervera R., Serrano R., Pons-Estel G.J., Et al., Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients, Ann Rheum Dis, 74, pp. 1011-1018, (2015)

[37]

Miyakis S., Lockshin M.D., Atsumi T., Et al., International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS), Thromb Haemost, 4, pp. 295-306, (2006)

[38]

Devreese K.M.J., Ortel T.L., Pengo V., de Laat B., Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH, J Thromb Haemost, 16, pp. 809-813, (2018)

[39]

Pengo V., Ruffatti A., Legnani C., Et al., Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study, Blood, 118, pp. 4714-4718, (2011)

[40]

Pengo V., Biasiolo A., Bison E., Chantarangkul V., Tripodi A., Antiphospholipid antibody ELISAs: survey on the performance of clinical laboratories assessed by using lyophilized affinity-purified IgG with anticardiolipin and anti-beta2-glycoprotein I activity, Thromb Res, 120, pp. 127-133, (2007)

← 1 2 3 4 5 6 7 8 9 10 →